SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	12 Months Ended					12 Months Ended		0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 2013	Jul. 26, 2013	Jan. 02, 2013	Dec. 31, 2013 Common stock warrants	Dec. 31, 2012 Common stock warrants	Jun. 28, 2013 MethylGene
Basis of presentation
Ratio of reverse split of the common shares								50
Exercisable ratio of outstanding options and warrants								50
Foreign currency translation
Net foreign exchange losses recognized in other income	$ 1,320,000	$ 12,000
Marketable securities and term deposits
Minimum original maturity period of marketable securities	90 days
Reclassification of Warrants
Warrant liability	33,407,000	0			16,200,000
Initial fair value of warrants recorded within stockholders equity that was reversed	0	11,153,000			11,200,000
Change in fair value related to periods prior to January 1, 2013 recorded as an increase to accumulated deficit					5,000,000
Change in fair value of warrant liability included in net loss	19,799,000	0				19,799,000	0
Reclassification of Share-based compensation liability
Share-based compensation liability				1,100,000
Increase in additional paid-in capital due to reclassification of share-based compensation liability	300,000
Increase in stock compensation expense	1,400,000
Fair value of liability options			$ 2,200,000